-
公开(公告)号：EP3507309B1
公开(公告)日：2020-09-30
申请号：EP16762775.1
申请日：2016-09-05
申请人： SORBONNE UNIVERSITE , Centre National de la Recherche Scientifique , Institut National de la Santé et de la Recherche Médicale (INSERM) , Assistance Publique - Hôpitaux De Paris , Université Paris Descartes
发明人： SOLLOGOUB, Matthieu , CALVEZ, Vincent , MARCELIN, Anne-Geneviève , BOUTEILLER, Laurent , MENAND, Mickaël , EVENOU, Pierre , GOTHLAND, Adélie , COLESNIC, Dmitri , ROSSIGNOL, Julien
IPC分类号： C08B37/16
-
公开(公告)号：EP3507309A1
公开(公告)日：2019-07-10
申请号：EP16762775.1
申请日：2016-09-05
申请人： SORBONNE UNIVERSITE , Centre National de la Recherche Scientifique , Institut National de la Santé et de la Recherche Médicale (INSERM) , Assistance Publique - Hôpitaux De Paris , Université Paris Descartes
发明人： SOLLOGOUB, Matthieu , CALVEZ, Vincent , MARCELIN, Anne-Geneviève , BOUTEILLER, Laurent , MENAND, Mickaël , EVENOU, Pierre , GOTHLAND, Adélie , COLESNIC, Dmitri , ROSSIGNOL, Julien
IPC分类号： C08B37/16
摘要： The invention relates to a capped cyclodextrin-hydrophobic moiety conjugate, to a supramolecular polymer formed of capped cyclodextrin-hydrophobic moiety conjugates according to the invention and to a siRNA-cyclodextrin complex comprising a supramolecular polymer according to the invention. The invention also relates to a method for manufacturing the capped cyclodextrin-hydrophobic moiety conjugate, the supramolecular polymer, the siRNA-cyclodextrin complex according to the invention. The capped cyclodextrin-hydrophobic moiety conjugate of the invention comprises a capped cyclodextrin group and at least one hydrophobic moiety bound by a first linker to one of the carbon atoms of the cap. The invention can be used for various applications in particular in the pharmaceutical field.
-
3.发明公开
公开(公告)号：EP3906415A1
公开(公告)日：2021-11-10
申请号：EP20700002.7
申请日：2020-01-02
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Assistance Publique-Hôpitaux de Paris (APHP) , Fondation Imagine , Université Paris Descartes , Centre National de la Recherche Scientifique (CNRS) , Université Paris-Saclay
发明人： HERMINE, Olivier , ROSSIGNOL, Julien , BELAID-CHOUCAIR, Zakia , FOUQUET, Guillemette , COURONNE, Lucile , DUSSIOT, Michael , RIGNAULT-BRICARD, Rachel , COMAN, Tereza , GUILLEM, Flavia , LEPELLETIER, Yves , RENAND, Amédée , MILPIED, Pierre
IPC分类号： G01N33/574
-
4.发明公开
公开(公告)号：EP3886983A1
公开(公告)日：2021-10-06
申请号：EP19809483.1
申请日：2019-11-28
申请人： Institut Gustave Roussy , ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS , Imagine Institut des Maladies Génétiques Necker Enfants Malades , Université de Paris , Centre national de la recherche scientifique , Institut National de la Santé et de la Recherche Médicale
IPC分类号： A61P7/06 , A61K31/138 , A61K38/20 , A61K38/18 , A61K38/19 , A61K45/06 , A61K31/135 , A61K31/15 , A61K31/343 , A61K31/4525
-
5.发明公开
公开(公告)号：EP4059569A1
公开(公告)日：2022-09-21
申请号：EP22157031.0
申请日：2020-01-02
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , Assistance Publique-Hôpitaux de Paris , Fondation Imagine , Centre national de la recherche scientifique , Université de Paris , Université Paris-Saclay
发明人： HERMINE, Olivier , ROSSIGNOL, Julien , BELAID-CHOUCAIR, Zakia , FOUQUET, Guillemette , COURONNE, Lucile , DUSSIOT, Michael , RIGNAULT-BRICARD, Rachel , COMAN, Tereza , GUILLEM, Flavia , LEPELLETIER, Yves , RENAND, Amédée , MILPIED, Pierre
IPC分类号： A61P35/00 , C07K16/28 , G01N33/574
摘要： Targeting immune checkpoints, such as Programmed cell Death 1 (PD1), has improved survival in cancer patients by unleashing exhausted CD8+ T-cell thereby restoring anti-tumor immune responses. Most patients, however, relapse or are refractory to immune checkpoint blocking therapies. Here, the inventors show that NRP1 is recruited in the cytolytic synapse of PD1+CD8+ T-cells, interacts and enhances PD-1 activity. In mice, CD8+ T-cell specific deletion of Nrp1 improves spontaneous and anti PD1 antibody anti-tumor immune responses. Likewise, in human metastatic melanoma, the expression of NRP1 in tumor infiltrating CD8+ T-cells predicts poor outcome of patients treated with anti-PDl (e.g. pembrolizumab). Finally, the combination of anti-NRPl and anti-PDl antibodies is synergistic in human, specifically in CD8+ T -cells anti-tumor response. Thus the therapeutic inhibition of NRP1 alone or combined with an immune checkpoint inhibitor (e.g. anti-PDl antibody) could efficiently repress tumor growth in human cancer. The present invention also relates to multispecific antibodies comprising at least one binding site that specifically binds to an immune checkpoint molecule (e.g. PD-1), and at least one binding site that specifically binds to NRP-1. The present invention also relates to a population of cells engineered to express a chimeric antigen receptor (CAR) and wherein the expression of NRP-1 in said cells is repressed.
-
6.发明公开
公开(公告)号：EP3659672A1
公开(公告)日：2020-06-03
申请号：EP18306579.6
申请日：2018-11-28
申请人： Institut Gustave Roussy , ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS , Imagine Institut des Maladies Génétiques Necker Enfants Malades , Institut National de la Santé et de la Recherche Médicale , UNIVERSITE PARIS DESCARTES , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
IPC分类号： A61P7/06 , A61K31/138 , A61K38/20 , A61K38/18 , A61K38/19 , A61K45/06 , A61K31/135 , A61K31/15 , A61K31/343 , A61K31/4525
摘要： The invention relates to the combined use of selective serotonin reuptake inhibitors (SSRIs) and hematopoietic growth factors as a drug and particularly for treating cytopenia related to hematopoietic diseases or chemotherapy, and also to a pharmaceutical kit comprising both SSRIs and hematopoietic growth factors. This combination is more particularly used for treating patients presenting cytopenia, and patients in need of chemotherapy and more particularly to reduce length of aplasia after chemotherapy.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.023 秒)
